Finance

Lists
HALO:NASDAQ
Halozyme Therapeutics, Inc.
၁၁၀.၇၉ US$
+၀.၉၈%
(+၁.၀၇) 1D
၁၁၀.၇၉ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၇, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HALO...
Open
၁၁၁.၆၂ US$
High
၁၁၄.၀၀ US$
Low
၁၁၀.၁၆ US$
Mkt. cap
ဋေ ၁.၂၆ ထ
Avg. vol.
၂.၂၃ သန်း
Volume
၂.၁၈ သန်း
P/E ratio
၃၃.၁၀
52-wk high
၁၁၆.၈၄ US$
52-wk low
၆၁.၂၂ US$
EPS
၃.၃၅ US$
Beta
၀.၈၈
Shares outstanding
၁၁.၃၅ ကုဋေ
No. of employees
၄၂၃
Open
၁၁၁.၆၂ US$
High
၁၁၄.၀၀ US$
Low
၁၁၀.၁၆ US$
Mkt. cap
ဋေ ၁.၂၆ ထ
Avg. vol.
၂.၂၃ သန်း
Volume
၂.၁၈ သန်း
P/E ratio
၃၃.၁၀
52-wk high
၁၁၆.၈၄ US$
52-wk low
၆၁.၂၂ US$
EPS
၃.၃၅ US$
Beta
၀.၈၈
Shares outstanding
၁၁.၃၅ ကုဋေ
No. of employees
၄၂၃
News stories
From web sources and news partners
Barron's
Barron's
·
ပြီးခဲ့သည့် ၈ နာရီ
Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
Euronext Markets: Real-time Stock Market Data | live
Euronext Markets: Real-time Stock Market Data | live
·
ပြီးခဲ့သည့် ၈ နာရီ
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Investing.com UK
Investing.com UK
·
ပြီးခဲ့သည့် ၁၂ နာရီ
Why is Halozyme Therapeutics stock climbing today? By Investing.com
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees၄၂၃
Founded၁၉၉၈
Headquartersဆန်ဒီရေဂို, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to HALO in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for HALO in the last 3 months.
Highest
Current ၁၁၀.၇၉ US$
၁၁၅.၀၀ US$ (+၃.၈၀%)
Average
၁၀၃.၈၃ US$ (-၆.၂၈%)
Lowest
၉၃.၀၀ US$ (-၁၆.၀၆%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
၁၁၅.၀၀ US$
+၃.၈%
10/07/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
၁၀၅.၀၀ US$
-၅.၂%
08/07/2026
David Risinger
Leerink Partners
Buy
Upgraded
၁၁၀.၀၀ US$
-၀.၇%
08/07/2026
Jason Butler
Citizens JMP
Buy
Maintained
၉၃.၀၀ US$
-၁၆.၁%
08/07/2026
Mohit Bansal
Wells Fargo
Hold
Reiterated
၉၅.၀၀ US$
-၁၄.၃%
08/07/2026
Brendan Smith
TD Cowen
Buy
Reiterated
၁၀၅.၀၀ US$
-၅.၂%
08/07/2026
Corinne Johnson
Goldman Sachs
Sell
Maintained
၅၇.၀၀ US$
-၄၈.၆%
06/14/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
၇၀.၀၀ US$
-၃၆.၈%
05/20/2026
Robert Wasserman
Benchmark Co.
Buy
Maintained
၉၀.၀၀ US$
-၁၈.၈%
02/19/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
၂.၂၈ US$ / ၁.၈၂ US$
+၂၅.၅၃%beat
Revenue / Est. (USD)
၄၈.၁၀ ကုဋေ / ၄၀.၀၃ ကုဋေ
+၂၀.၁၅%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၃၅.၄၃ ကုဋေ
၄၅.၁၈ ကုဋေ
၃၇.၆၇ ကုဋေ
၄၈.၁၀ ကုဋေ
Cost of goods sold
၇.၂၅ ကုဋေ
၁၁.၀၇ ကုဋေ
၁၀.၄၈ ကုဋေ
၁၀.၆၈ ကုဋေ
Cost of revenue
၇.၂၅ ကုဋေ
၁၁.၀၇ ကုဋေ
၁၀.၄၈ ကုဋေ
၁၀.၆၈ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၄.၆၁ ကုဋေ
၆.၃၃ ကုဋေ
၅.၇၉ ကုဋေ
၅.၇၀ ကုဋေ
Operating expense
၆.၃၈ ကုဋေ
၈.၆၇ ကုဋေ
၈.၇၄ ကုဋေ
၈.၆၅ ကုဋေ
Total operating expenses
၁၃.၆၃ ကုဋေ
၁၉.၇၄ ကုဋေ
၁၉.၂၂ ကုဋေ
၁၉.၃၃ ကုဋေ
Operating income
၂၁.၇၉ ကုဋေ
၂၅.၄၄ ကုဋေ
၁၈.၄၅ ကုဋေ
၂၈.၇၇ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
၂၁.၉၀ ကုဋေ
-၁၀.၀၈ ကုဋေ
၁၈.၀၃ ကုဋေ
၂၈.၄၉ ကုဋေ
EBT excluding unusual items
၂၁.၉၀ ကုဋေ
၂၅.၁၆ ကုဋေ
၁၈.၀၃ ကုဋေ
၂၈.၄၉ ကုဋေ
Income tax expense
၄.၃၇ ကုဋေ
၄.၀၇ ကုဋေ
၃.၀၃ ကုဋေ
၅.၅၀ ကုဋေ
Effective tax rate
၁၉.၉၇%
-၄၀.၄၀%
၁၆.၇၉%
၁၉.၃၀%
Other operating expenses
-
-
-
-
Net income
၁၇.၅၂ ကုဋေ
-၁၄.၁၆ ကုဋေ
၁၅.၀၀ ကုဋေ
၂၂.၉၉ ကုဋေ
Net profit margin
၄၉.၄၆%
-၃၁.၃၄%
၃၉.၈၃%
၄၇.၈၀%
Earnings per share
၁.၇၂
-၀.၂၄
၁.၆၀
၂.၂၈
Interest and investment income
၅.၃၃ သန်း
၂.၀၉ သန်း
၁.၂၉ သန်း
၂.၈၄ သန်း
Interest expense
-၄.၃၀ သန်း
-၄.၉၁ သန်း
-၅.၅၁ သန်း
-၅.၅၉ သန်း
Net interest expenses
၁.၀၄ သန်း
-၂.၈၂ သန်း
-၄.၂၂ သန်း
-၂.၇၅ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
၂၃.၆၈ ကုဋေ
၂၇.၉၁ ကုဋေ
၂၁.၅၆ ကုဋေ
၃၁.၉၁ ကုဋေ
Gain or loss from assets sale
-
၂.၆၂ သန်း
-
၇.၆၀ သောင်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ